FirstWord

The collaboration is focused on developing small molecule therapies against promising, but historically undruggable oncology targets.

An accelerated filing for RGX-202 was planned for the first half of 2027, but has now been brought forward to the third quarter of this year.

RQ Bio's lead programme, the long-acting mAb RQB01, is designed to deliver potent and broad protection against flu in a single dose.

Global Phase III trials evaluating OLN324 in diabetic macular oedema and wet age-related macular degeneration are slated to start next half.

The Chinese biotech will lead discovery and early development efforts for Lilly-selected therapeutic targets.

Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaborationStrategic partnership spans regulatory, marketing, distribution, and revenue sharin...

Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational...

Collaboration combines Saudi Arabia's national health data capabilities with Flagship's life sciences and AI-enabled innovation expertise to accelerate precision medicine, scientific discovery, and bi...

FairJourney Bio brings AbTherx’s Atlas transgenic mouse technologies in-house, enabling partner programmes to run from immunisation to a developability-assessed lead in one continuous workflowPartners...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMIN...